| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/07/2001 | CN1283181A Substituted beta-alanines |
| 02/07/2001 | CN1283180A Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas |
| 02/07/2001 | CN1283120A CD8 as inhibitor of cellular immune system |
| 02/07/2001 | CN1283116A Method of reducing craving in mamals |
| 02/07/2001 | CN1283115A Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| 02/07/2001 | CN1283114A Benzoxazine compounds for enhancing synaptic response |
| 02/07/2001 | CN1283111A Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| 02/07/2001 | CN1283108A I (chlamydia) protein, gene sequence and uses thereof |
| 02/07/2001 | CN1282737A Intermediate product used for preparing substituted quinoline-2-formamide |
| 02/07/2001 | CN1282581A Medicine composition |
| 02/07/2001 | CN1061656C Drocess for preparation of tetrazole derivatives in two crystalline forms and novel crystalline form of said derivative |
| 02/07/2001 | CN1061655C Method for preparing cycloheptimidazole derivatives |
| 02/07/2001 | CN1061653C Benzofuran compounds, process for their preparation and pharmaceutical compositions thereof |
| 02/07/2001 | CN1061652C Endotheliomycine receptor antagonist |
| 02/07/2001 | CN1061561C Health-care wine |
| 02/07/2001 | CN1061557C Capsule of ginkgo and garlic extracts |
| 02/07/2001 | CN1061556C Gingko-Ribes burejense capsule |
| 02/07/2001 | CN1061539C Vitalizing health-care liquid |
| 02/06/2001 | US6184422 Cyclohexanediol derivatives |
| 02/06/2001 | US6184397 Preparation of sterol and stanol-esters |
| 02/06/2001 | US6184389 Feature a plurality of functional groups attached to backbone and phosphoramidate sites |
| 02/06/2001 | US6184368 Polyvalent carbohydrate molecules |
| 02/06/2001 | US6184352 Adseverin protein |
| 02/06/2001 | US6184351 Artificial brain protein; for the treatment of alzheimer's and parkinson's disease |
| 02/06/2001 | US6184346 Peptide of defined amino acid sequence which inhibits elastase and subtilisin; use as drug because of low molecular weight |
| 02/06/2001 | US6184255 Enhanced absorption |
| 02/06/2001 | US6184252 2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss |
| 02/06/2001 | US6184248 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 02/06/2001 | US6184247 Method of increasing cell renewal rate |
| 02/06/2001 | US6184244 C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/06/2001 | US6184236 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative |
| 02/06/2001 | US6184231 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 02/06/2001 | US6184229 For treatment of disorders associated with the disfunctioning of nicotinic receptors |
| 02/06/2001 | US6184226 Antiinflammatory agents for treatment of cardiovascular system disorders/respiratory system disorders, antiischemic agents |
| 02/06/2001 | US6184223 Reverse-turn mimetics and methods relating thereto |
| 02/06/2001 | US6184222 Administering norepinephrine reuptake inhibitor selective for norepinephrine over other neurotransmitters; side effect reduction |
| 02/06/2001 | US6184217 Administering antiinflammatory dosage of a ring-substituted indolocarbazole derivative compound; tumor necrosis factor (tnf) inhibitors |
| 02/06/2001 | US6184215 Treatment of skin conditions with oxysterol activators of LXRα |
| 02/06/2001 | US6184207 A peptide including specified piperidine-containing group, having an n-terminal hydrophobic residue and optionally an amidated c-terminal of specified end groups; treating multiple sclerosis or rheumatoid arthritis |
| 02/06/2001 | US6183993 Complement-resistant non-mammalian DNA viruses and uses thereof |
| 02/06/2001 | US6183991 Nucleotide and amino acid sequence; recombinant production of polypeptide; enhancing viability of cryopreserved sperm, sperm motility, and fertilization in assisted reproduction; contraceptives |
| 02/06/2001 | US6183744 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 02/06/2001 | CA2314798A1 1,2,4,5-tetrahydro-benzo[d]azepin derivatives |
| 02/06/2001 | CA2220696C Improved method for controlling ectoparasites |
| 02/06/2001 | CA2217768C Flavorful zinc compositions for oral use incorporating copper |
| 02/06/2001 | CA2141572C Terfenadine metabolites and their optically pure isomers for treating allergic disorders |
| 02/06/2001 | CA2003538C Collagen-polymer conjugates |
| 02/05/2001 | CA2314867A1 2,7-substituted octahydro-1h-pyrido¬1,2-a|pyrazine derivatives as ligands for serotonin receptors |
| 02/01/2001 | WO2001007656A1 Antisense modulation of shp-1 expression |
| 02/01/2001 | WO2001007646A2 Method for quantization of the antiviral effect of antiviral active principles |
| 02/01/2001 | WO2001007637A2 Conditionally controlled, attenuated hiv vaccine |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007627A1 Drosophila recombination-associated protein and methods for use |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007611A2 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | WO2001007604A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | WO2001007602A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | WO2001007595A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | WO2001007568A2 Muscle cells and their use in cardiac repair |
| 02/01/2001 | WO2001007481A1 Antitumor antibodies, proteins, and uses thereof |
| 02/01/2001 | WO2001007479A2 Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases |
| 02/01/2001 | WO2001007477A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007475A1 Novel peptides |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007457A1 Antisense modulation of pten expression |
| 02/01/2001 | WO2001007456A1 Antisense modulation of jun n-terminal kinase kinase-1 expression |
| 02/01/2001 | WO2001007454A1 Enzyme catalyzed therapeutic activation |
| 02/01/2001 | WO2001007442A1 Beta-amyloid peptide inhibitors |
| 02/01/2001 | WO2001007440A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 02/01/2001 | WO2001007436A2 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | WO2001007434A2 Indole derivatives and their use as 5ht2a ligands |
| 02/01/2001 | WO2001007424A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 02/01/2001 | WO2001007423A1 Drug compositions exhibiting thrombopoietin agonism |
| 02/01/2001 | WO2001007419A1 Novel thiazine or pyrazine derivatives |
| 02/01/2001 | WO2001007417A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 02/01/2001 | WO2001007411A1 Biarylurea derivatives |
| 02/01/2001 | WO2001007406A1 Novel amide derivatives |
| 02/01/2001 | WO2001007400A1 Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient |
| 02/01/2001 | WO2001007088A2 Methods for treating therapy-resistant tumors |
| 02/01/2001 | WO2001007087A2 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | WO2001007074A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007069A1 In vivo induction for enhanced function of isolated hepatocytes |
| 02/01/2001 | WO2001007067A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007065A2 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 02/01/2001 | WO2001007050A1 Nociceptin receptor orl-1 agonists for use in treating cough |
| 02/01/2001 | WO2001007043A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 02/01/2001 | WO2001007042A1 Apicidin-derived cyclic tetrapeptides |
| 02/01/2001 | WO2001007040A1 Multidrug-resistant cancer overcoming agents and process for producing the same |
| 02/01/2001 | WO2001007036A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN |
| 02/01/2001 | WO2001007031A1 Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same |
| 02/01/2001 | WO2001007030A2 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs |
| 02/01/2001 | WO2001007029A2 Substituted guanidines and the use thereof |
| 02/01/2001 | WO2001007020A2 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof |
| 02/01/2001 | WO2001006984A2 Small molecules useful in the treatment of inflammatory disease |
| 02/01/2001 | WO2000067735A3 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION |
| 02/01/2001 | WO2000059493A3 Improved dialysis solutions and methods |
| 02/01/2001 | WO2000049043A3 Human lipid-associated proteins |
| 02/01/2001 | WO2000038717A3 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 02/01/2001 | WO2000037107A3 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |